SPOTLIGHT: KV buys U.S. rights to EvaMist


KV Pharmaceutical has wrapped a deal with VIVUS to buy the U.S. marketing rights to EvaMist, an estrogen transdermal spray developed to treat vasomotor symptoms associated with menopause. KV agreed to pay $10 million at closing and to make an additional payment of approximately $140 million at the time of final approval from the FDA. There are also two, one-time milestone payments tied to the net sales of the product. $10 million will be paid if the product achieves $100 million in net sales in a market year and up to $20 million will be paid if the product achieves $200 million in net sales in a market year. Release

Suggested Articles

Silverback Therapeutics reeled in $85 million to advance its lead antibody-drug conjugate through the clinic and develop its earlier-stage pipeline.

The reported requirements suggest a company is unlikely to have the data needed to support an EUA before the election in six weeks.  

Blocking tau appears to be just as fruitless as clearing amyloid buildup when it comes to helping Alzheimer’s disease patients.